drugset / Trial / NCT00805467
Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.
Timeline
- Start
- 2008-08
- Primary completion
- 2013-08
- Completion
- 2013-08
Outcome
Outcome not reported
Stopped: “AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostamatinib | Small molecule | 50 mg | Oral |
| Subject | Fostamatinib | Small molecule | 100 mg | Oral |
| Subject | Fostamatinib | Small molecule | 150 mg | Oral |